For research use only. Not for therapeutic Use.
CBR-2092, also known as TNP-2092, is a DNA topoisomerase inhibitor and DNA-directed RNA polymerase inhibitor potentially for the treatment of bacterial infections. CBR-2092 exhibited rifampin-like potency as an inhibitor of RNA polymerase, was an equipotent (balanced) inhibitor of DNA gyrase and DNA topoisomerase IV, and retained activity against a prevalent quinolone-resistant variant. Macromolecular biosynthesis studies confirmed that CBR-2092 has rifampin-like effects on RNA synthesis in rifampin-susceptible strains and quinolone-like effects on DNA synthesis in rifampin-resistant strains. Studies of mutant strains that exhibited reduced susceptibility to CBR-2092 further substantiated RNA polymerase as the primary cellular target of CBR-2092, with DNA gyrase and DNA topoisomerase IV being secondary and tertiary targets, respectively, in strains exhibiting preexisting rifampin resistance. In contrast to quinolone comparator agents, no strains with altered susceptibility to CBR-2092 were found to exhibit changes consistent with altered efflux properties.
| Catalog Number | I005737 |
| CAS Number | 922717-97-3 |
| Synonyms | CBR-2092; CBR 2092; CBR2092; TNP-2092; TNP 2092; TNP2092;Rifamycin, 3-[(E)-[[4-[[1-[(3R)-1-(3-carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl] cyclopropyl]methylamino]-1-piperidinyl]imino]methyl]- |
| Molecular Formula | C65H81FN6O15 |
| Purity | ≥95% |
| Target | Cell Cycle/DNA Damage |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term ,or -20 °C for long term |
| InChI | InChI=1S/C65H81FN6O15/c1-31-13-12-14-32(2)61(80)68-50-44(56(77)47-48(57(50)78)55(76)37(7)59-49(47)60(79)64(9,87-59)85-26-20-46(84-11)33(3)58(86-38(8)73)36(6)54(75)35(5)53(31)74)28-67-71-24-18-41(19-25-71)69(10)65(21-22-65)40-17-23-70(29-40)52-34(4)51-42(3 |
| InChIKey | OPZFMLLAJBIKAN-KYGXCNJYSA-N |
| SMILES | CC1=C(O[C@@]2(C)C3=O)C3=C(C(O)=C(/C=N/N4CCC(N(C)C5([C@@H]6CCN(C7=C(C)C(N8C=C7F)=C(C9CC9)C=C(C(O)=O)C8=O)C6)CC5)CC4)C(NC(/C(C)=CC=C[C@H](C)[C@@H]([C@@H](C)[C@@H](O)[C@H]([C@@H]([C@H](C)[C@@H](OC)/C=C/O2)OC(C)=O)C)O)=O)=C%10O)C%10=C1O |
| Reference | </br>1:In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS.Antimicrob Agents Chemother. 2008 Jul;52(7):2313-23. doi: 10.1128/AAC.01649-07. Epub 2008 Apr 28. PMID: 18443108 Free PMC Article</br>2:In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS.Antimicrob Agents Chemother. 2008 Jul;52(7):2324-34. doi: 10.1128/AAC.01651-07. Epub 2008 Apr 28. PMID: 18443106 Free PMC Article |
